We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03442751
Recruitment Status : Completed
First Posted : February 22, 2018
Last Update Posted : May 27, 2022
Information provided by (Responsible Party):
Glaukos Corporation

Brief Summary:
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.

Condition or disease Intervention/treatment Phase
Progressive Keratoconus Drug: Paracel 1 Drug: Paracel Placebo Drug: Paracel 2 R0185 Device: KXL High Power System (2 J) Device: KXL High Power System (10 J) Phase 3

Detailed Description:
Up to 275 study eyes with progressive keratoconus will be enrolled. Study eyes will be randomized in a 2:1 ratio to receive CXL treatment or sham/control treatment.The primary efficacy endpoint is a difference of ≥ 1 diopter between treatment groups in the mean change in Kmax from baseline to Month 6.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 279 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus
Actual Study Start Date : April 6, 2018
Actual Primary Completion Date : November 1, 2019
Actual Study Completion Date : August 10, 2020

Arm Intervention/treatment
Active Comparator: Epithelium-on CXL Treatment Group
Study eye receives Paracel 1, Paracel 2 R0185 and irradiated using KXL High Power System (10 J)
Drug: Paracel 1
Two drops every 60 seconds for 4 minutes
Other Name: 0.250% riboflavin ophthalmic solution

Drug: Paracel 2 R0185
Two drops every 30 seconds for 6 minutes
Other Name: 0.185% riboflavin ophthalmic solution

Device: KXL High Power System (10 J)
30 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 10 J/cm2)
Other Name: UVA Irradiation

Sham Comparator: Sham Treatment/Control Group
Sham eye receives Paracel Placebo and irradiated using KXL High Power System (2 J)
Drug: Paracel Placebo
Two drops of Paracel Placebo every 60 seconds for 4 minutes followed by two drops every 30 seconds for 6 minutes
Other Name: 0.0% riboflavin ophthalmic solution

Device: KXL High Power System (2 J)
6 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 2 J/cm2)
Other Name: Ultraviolet-A (UVA) Irradiation

Primary Outcome Measures :
  1. Kmax [ Time Frame: 6 months ]
    Mean difference of at least 1 diopter in Kmax change from baseline between treatment groups

Secondary Outcome Measures :
  1. Kmax [ Time Frame: 12 months ]
    Change from baseline in Kmax between treatment groups

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be between 12 and 55 years of age, male or female, of any race;
  2. Provide written informed consent and sign a HIPAA form. Subjects who are under the age of 18 (or have not yet reached the age of majority per local regulations) will need to sign an assent form as well as having a parent or legal guardian sign an informed consent
  3. Ability to read English or Spanish to complete the NEI-VFQ 25 questionnaire;
  4. Willingness and ability to follow all instructions and comply with schedule for follow-up visits;
  5. For females capable of becoming pregnant, agree to have urine pregnancy testing performed prior to randomization of each study eye and prior to treatment of a cross-over eye; must not be lactating, and must agree to use a medically acceptable form of birth control for at least one week prior to the randomization visit, one week prior to treatment of a cross-over eye, and continue to use the method for one month following the last treatment. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
  6. Having topographic and clinical evidence of keratoconus defined as thefollowing:

    • Axial topography consistent with keratoconus
    • Maximum corneal curvature, as measured by Kmax of ≥ 47.00 D;
    • Presence of central or inferior steepening on the Pentacam topography map
    • Presence of one or more findings associated with keratoconus, such as

      1. Fleischer ring
      2. Vogt striae
      3. Corneal thinning
      4. Corneal scarring
      5. Scissoring of the retinoscopic reflex
  7. Having a diagnosis of progressive keratoconus, defined as one or more of the following changes over a period of 18 months or less:

    1. An increase of ≥ 1.00 D in Kmax or simK
    2. An increase of ≥ 1.00 D in regular astigmatism on subjective manifest refraction
    3. A myopic shift (towards greater negative sphere) of 0.50 D or more on subjective manifest refraction or as evaluated by comparing eyeglass or contact lens prescriptions to current subjective manifest refraction [NOTE: subjects with a clear history of progression but without prior documentation may be screened and followed for a period of time to confirm and document progression]
  8. BSCVA of ≥ 1 letter and ≤ 85 letters on ETDRS chart
  9. Contact Lens Wearers Only: Removal of contact lenses is required for a 1 week period prior to the screening visit(s) and subject must agree to remain out of their contact lenses from the time of treatment until the 1-month visit is completed. A contact lens wearer is defined as someone who has worn contact lenses in the eye to be treated in the last 30 days.

Exclusion Criteria:

  1. Contraindications, sensitivity or known allergy to the use of the test article(s) or their components;
  2. If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test prior to the randomization or treatment of either eye or during the course of the study;
  3. Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme;
  4. A history of previous corneal surgery, limbal relaxing incision procedure, or insertion of Intacs in the eye(s) to be treated;
  5. Corneal pachymetry that is < 325 microns at the thinnest point measured by Pentacam in the eye to be treated;
  6. Eyes which are aphakic, or eyes which are pseudophakic and do not have a UV blocking lens implanted;
  7. Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example:

    • History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, corneal melt, corneal dystrophy, etc.);
    • Clinically significant corneal scarring in the cross-linking treatment zone that is not related to keratoconus or, in the Investigator's opinion, will interfere with the cross-linking procedure;
  8. A history of delayed epithelial healing in the eye to be treated or a current condition that may interfere with or prolong epithelial healing;
  9. Subjects with nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests;
  10. A history of previous corneal cross-linking treatment in the eye to be treated;
  11. Have used an investigational drug or device within 30 days of screening or be concurrently enrolled in another investigational drug or device trial within 30 days of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03442751

Layout table for location information
United States, California
Stanford University School of Medicine
Palo Alto, California, United States, 94303
United States, Florida
Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
United States, Massachusetts
Ophthalmic Consultants of Boston
Waltham, Massachusetts, United States, 02451
United States, Minnesota
Chu Vision Institute
Bloomington, Minnesota, United States, 55420
Minnesota Eye Consultants
Minnetonka, Minnesota, United States, 55305
United States, Ohio
Comprehensive EyeCare of Central Ohio
Westerville, Ohio, United States, 43082
United States, Pennsylvania
Vantage Eye Care, LLC
Bala-Cynwyd, Pennsylvania, United States, 19004
UPMC Eye Center
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Carolina Cataract and Laser Center
Ladson, South Carolina, United States, 29456
United States, South Dakota
Vance Thompson Vision
Sioux Falls, South Dakota, United States, 57108
United States, Texas
Slade and Baker Vision Center
Houston, Texas, United States, 77027
Focal Point Vision
San Antonio, Texas, United States, 78209
United States, Utah
Hoopes Vision
Draper, Utah, United States, 84020
United States, Virginia
See Clearly Vision Group
McLean, Virginia, United States, 22102
Sponsors and Collaborators
Glaukos Corporation
Layout table for investigator information
Study Director: Kerry Stephens, OD Glaukos Corporation
Layout table for additonal information
Responsible Party: Glaukos Corporation
ClinicalTrials.gov Identifier: NCT03442751    
Other Study ID Numbers: ACP-KXL-308
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: May 27, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Corneal Diseases
Eye Diseases
Pharmaceutical Solutions
Ophthalmic Solutions
Vitamin B Complex
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents